<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Med</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id><journal-id journal-id-type="publisher-id">CAM4</journal-id><journal-title-group><journal-title>Cancer Medicine</journal-title></journal-title-group><issn pub-type="epub">2045-7634</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28879665</article-id><article-id pub-id-type="pmc">5633545</article-id><article-id pub-id-type="doi">10.1002/cam4.1153</article-id><article-id pub-id-type="publisher-id">CAM41153</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Prevention</subject><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Effects of low&#x02010;to&#x02010;moderate alcohol supplementation on urinary estrogen metabolites in postmenopausal women in a controlled feeding study</article-title><alt-title alt-title-type="left-running-head">S. Mahabir et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="cam41153-cr-0001" contrib-type="author" corresp="yes"><name><surname>Mahabir</surname><given-names>Somdat</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0013-248X</contrib-id><address><email>mahabir@mail.nih.gov</email></address><xref ref-type="aff" rid="cam41153-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="cam41153-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cam41153-cr-0002" contrib-type="author"><name><surname>Pfeiffer</surname><given-names>Ruth</given-names></name><xref ref-type="aff" rid="cam41153-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="cam41153-cr-0003" contrib-type="author"><name><surname>Xu</surname><given-names>Xia</given-names></name><xref ref-type="aff" rid="cam41153-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="cam41153-cr-0004" contrib-type="author"><name><surname>Baer</surname><given-names>David J.</given-names></name><xref ref-type="aff" rid="cam41153-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="cam41153-cr-0005" contrib-type="author"><name><surname>Taylor</surname><given-names>Philip R.</given-names></name><xref ref-type="aff" rid="cam41153-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="cam41153-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Environmental Epidemiology Branch</named-content>
<named-content content-type="organisation-division">Epidemiology and Genomics Research Program</named-content>
<named-content content-type="organisation-division">Division of Cancer Control and Population Sciences</named-content>
<institution>National Cancer Institute (NCI)</institution>
<named-content content-type="city">Rockville</named-content>
<named-content content-type="country-part">Maryland</named-content>
</aff><aff id="cam41153-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Genetic Epidemiology Branch</named-content>
<named-content content-type="organisation-division">Division of Cancer Epidemiology and Genetics</named-content>
<institution>NCI</institution>
<named-content content-type="city">Rockville</named-content>
<named-content content-type="country-part">Maryland</named-content>
</aff><aff id="cam41153-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Biostatistics Branch</named-content>
<named-content content-type="organisation-division">Division of Cancer Epidemiology and Genetics</named-content>
<institution>NCI</institution>
<named-content content-type="city">Rockville</named-content>
<named-content content-type="country-part">Maryland</named-content>
</aff><aff id="cam41153-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Cancer Research Technology Program</named-content>
<named-content content-type="organisation-division">Leidos Biomedical Research, Inc.</named-content>
<institution>Frederick National Laboratory for Cancer Research</institution>
<named-content content-type="city">Frederick</named-content>
<named-content content-type="country-part">Maryland</named-content>
</aff><aff id="cam41153-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Agricultural Research Service</named-content>
<institution>United States Department of Agriculture</institution>
<named-content content-type="city">Beltsville</named-content>
<named-content content-type="country-part">Maryland</named-content>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Somdat Mahabir, Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 4E106, Rockville, MD 20892&#x02010;9738. Tel: 240&#x02010;276&#x02010;6941; E&#x02010;mail: <email>mahabir@mail.nih.gov</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2017</year></pub-date><volume>6</volume><issue>10</issue><issue-id pub-id-type="doi">10.1002/cam4.2017.6.issue-10</issue-id><fpage>2419</fpage><lpage>2423</lpage><history><date date-type="received"><day>14</day><month>2</month><year>2017</year></date><date date-type="rev-recd"><day>19</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>11</day><month>7</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 Published by John Wiley & Sons Ltd. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Cancer Medicine</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAM4-6-2419.pdf"/><abstract id="cam41153-abs-0001"><title>Abstract</title><p>Heavy alcohol drinking is associated with increased breast cancer risk, but associations with low&#x02010;to&#x02010;moderate alcohol consumption are less clear and the biological mechanisms are not well defined. The objective of this study was to evaluate the effects of 8&#x000a0;weeks of low (15&#x000a0;g/d) and moderate (30&#x000a0;g/d) alcohol ingestion on concentrations of 15 urinary estrogen metabolites (EMs) in postmenopausal women (<italic>n</italic>&#x000a0;=&#x000a0;51) in a controlled feeding study with a randomized crossover design. Compared to no alcohol, 15&#x000a0;g/day for 8&#x000a0;weeks had no effect on urinary EMs. However, compared to no alcohol, 30&#x000a0;g/day for 8&#x000a0;weeks decreased urinary 2&#x02010;hydroestrone (2&#x02010;OHE1) by 3.3% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.055) and increased 16&#x02010;epiestriol (16&#x02010;EpiE3) by 26.6% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.037). Trends for reduced urinary 2&#x02010;OHE1 (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.045), reduced ratio of 2&#x02010;OH:16OH pathways (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.008), and increased 16&#x02010;EpiE3 (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.035) were observed as alcohol ingestion increased from 0&#x000a0;g to 15&#x000a0;g to 30&#x000a0;g/d. Moderate alcohol consumption for 8&#x000a0;weeks had modest effects on urinary concentrations of 2&#x02010;OHE1 and 16&#x02010;EpiE3 among postmenopausal women in a carefully controlled feeding study.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cam41153-kwd-0001">Low&#x02010;to&#x02010;moderate alcohol</kwd><kwd id="cam41153-kwd-0002">urinary estrogen metabolites</kwd><kwd id="cam41153-kwd-0003">postmenopausal women</kwd><kwd id="cam41153-kwd-0004">controlled feeding study</kwd></kwd-group><funding-group><award-group><funding-source>NIH and the National Cancer Institute Interagency Agreement Y1&#x02010;SC&#x02010;8012</funding-source></award-group></funding-group><counts><fig-count count="0"/><table-count count="2"/><page-count count="5"/><word-count count="3667"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>cam41153</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.1 mode:remove_FC converted:09.10.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="cam41153-cit-1001">
<source>Cancer Medicine</source>
<year>2017</year>; 6(10):<fpage>2419</fpage>&#x02013;<lpage>2423</lpage>
</mixed-citation>
</p></notes></front><body><sec id="cam41153-sec-0001"><title>Introduction</title><p>The link between low&#x02010;to&#x02010;moderate alcohol consumption and postmenopausal breast cancer risk remains unclear, possibly because of limitations in epidemiological study designs. Since exposure to endogenous and exogenous estrogens and increased urinary estrogens <xref rid="cam41153-bib-0001" ref-type="ref">1</xref> are important risk factors for breast cancer, clear evidence from controlled trials that low&#x02010;to&#x02010;moderate alcohol consumption increases concentrations of estrogens related to breast cancer would suggest a mechanism by which alcohol dose and duration of intake could increase risk, and provide support for a causal relationship.</p><p>Metabolism of parent estrogens, estrone (E1) and estradiol (E2) leads to the production of several estrogen metabolities (EM) in the urine. Endogenous estrogen metabolism pathways have previously been described <xref rid="cam41153-bib-0002" ref-type="ref">2</xref>, <xref rid="cam41153-bib-0003" ref-type="ref">3</xref>. Several of the estrogen metabolites in urine are hypothesized to increase breast cancer risk due to their estrogenic and genotoxic activities <xref rid="cam41153-bib-0003" ref-type="ref">3</xref>, <xref rid="cam41153-bib-0004" ref-type="ref">4</xref>. Mechanistically, estrogens may increase breast cancer risk in postmenopausal women via DNA damage <xref rid="cam41153-bib-0005" ref-type="ref">5</xref>, regulation of cell signaling pathways <xref rid="cam41153-bib-0006" ref-type="ref">6</xref>, and regulation of angiogenesis <xref rid="cam41153-bib-0007" ref-type="ref">7</xref>, possibly by an estrogen&#x02010;driven angiogenic switch <xref rid="cam41153-bib-0008" ref-type="ref">8</xref>.</p><p>From the Women's Alcohol Study (WAS), we previously reported increased serum estrone sulfate and DHEAS concentrations after 8&#x000a0;weeks <xref rid="cam41153-bib-0009" ref-type="ref">9</xref> and as short as 4&#x000a0;weeks <xref rid="cam41153-bib-0010" ref-type="ref">10</xref> of low (15&#x000a0;g/d) to moderate (30&#x000a0;g/d) alcohol consumption. We now report on the effects of low&#x02010;to&#x02010;moderate alcohol supplementation for 8&#x000a0;weeks on the concentrations of 15 urinary estrogen metabolites (EMs) including 2, 4, and 16&#x02010;hydroxylation pathways. Our secondary objective was to assess the effects of obesity on concentrations of urinary estrogen metabolites within each alcohol treatment group because there is considerable evidence that the risk of postmenopausal breast cancer is independently increased by obesity <xref rid="cam41153-bib-0011" ref-type="ref">11</xref>.</p></sec><sec id="cam41153-sec-0002"><title>Subjects and Methods</title><sec id="cam41153-sec-0003"><title>The Women's Alcohol Study</title><p>Details of the postmenopausal WAS has previously been described <xref rid="cam41153-bib-0009" ref-type="ref">9</xref>. In brief, the WAS feeding study used a crossover design in which 65 healthy postmenopausal women were randomly assigned to control (0&#x000a0;g), 15&#x000a0;g/d and 30&#x000a0;g/d alcohol treatments in random order with a 2&#x02013;5&#x000a0;weeks no alcohol washout periods between treatments. For the 0&#x02010; and 15&#x02010;g alcohol periods, energy from alcohol was replaced with carbohydrates (Polycose and soft drinks). Of the 65 women, 63 began the controlled feeding study and 53 successfully completed it. Blood and urine samples were collected at baseline and week 8 of the study and were stored at &#x02212;85&#x000b0;C. At the end of each 8&#x02010;week period, three 24&#x02010;h urine samples were collected, volume was measured, and aliquots were pooled for analysis.</p></sec><sec id="cam41153-sec-0004"><title>Assessment of urinary estrogen metabolites</title><p>At the end of each 8&#x02010;week period, three 24&#x02010;h urine samples were collected and aliquots were pooled and stored at &#x02212;85&#x000b0;C until thawed for analysis. Samples were sent in 10 batches to the Laboratory of Proteomics and Analytical Chemistry, Leidos Biomedical Research, Inc. for measurement using a high&#x02010;performance liquid chromatography&#x02010;tandem mass spectrometry (LC&#x02010;MS/MS) method which measures EMs <xref rid="cam41153-bib-0012" ref-type="ref">12</xref>. Urinary EM concentrations were adjusted for creatinine.</p><p>For the LC&#x02013;MS/MS assays, four blinded quality control (QC) samples were inserted in each of the 10 batches of urine samples analyzed. The coefficients of variation (CVs) within batches were as follows: 16&#x003b1;&#x02010;Hydroxyestrone (16&#x003b1;&#x02010;OHE1) (0.06&#x02013;2.4%), 16&#x02010;Epiestriol (16&#x02010;epiE3) (0.09&#x02013;2.1%), 16&#x02010;Ketoestradiol (16&#x02010;ketoE2) (0.03&#x02013;1.7%), 17&#x02010;Epiestriol (17&#x02010;epiE3) (0.14&#x02013;2.5%), 2&#x02010;Methoxyestrone (2&#x02010;MeOE1) (0.04&#x02013;1.4%), 2&#x02010;Methoxyestradiol (2&#x02010;MeOE2) (0.3&#x02013;4.6%), 2&#x02010;Hydroxyestrone (2&#x02010;OHE1) (0.03&#x02013;0.7%), 2&#x02010;Hydroxyestradiol (2&#x02010;OHE2) (0.2&#x02013;4.0%), 2&#x02010;Hydroxyestrone&#x02010;3&#x02010;methyl ether (3&#x02010;MeOE1) (0.1&#x02013;3.2%), 4&#x02010;Methoxyestrone (4&#x02010;MeOE1) (0.1&#x02013;2.6%), 4&#x02010;Methoxyestradiol (4&#x02010;MeOE2) (0.3&#x02013;6.7%), 4&#x02010;Hydroxyestrone (4&#x02010;OHE1) (0.3&#x02013;1.2%), Estrone (E1) (0.01&#x02013;1.5%), Estradiol (E2) (0.2&#x02013;2.2%), and Estriol (E3) (0.05&#x02013;1.3%).</p></sec><sec id="cam41153-sec-0005"><title>Statistical analyses</title><p>Urinary EM concentrations were transformed using the Box&#x02010;Cox transformation to normalize their distributions. Mixed models were fitted to the transformed EMs adjusted for race and age in four categories defined by quartiles (&#x02264;53.9, 54&#x02013;58.2, 58.3&#x02013;63.6, &#x0003e;63.6&#x000a0;years), body mass index (BMI), and baseline values for each analyte using restricted maximum likelihood. In analyses that assessed the impact of BMI on EM concentrations, we fit separate linear regression models to each alcohol category adjusted for age and race, if appropriate. For the trend test, BMI categories were coded as 0, 1, and 2, and a Wald <italic>P</italic>&#x02010;value was calculated. Statistical analyses were conducted using SAS software (SAS/Stat version 9.1; SAS Institute, Cary, NC, USA).</p></sec></sec><sec id="cam41153-sec-0006"><title>Results</title><p>Fifty&#x02010;one women had urinary EM measurements for all three treatments, as well as baseline urinary EM. Characteristics of the 51 study participants and their baseline urinary EM measurements are shown in Table&#x000a0;<xref rid="cam41153-tbl-0001" ref-type="table-wrap">1</xref>. At baseline, as expected, there was wide variation in urinary EM concentrations overall and in Whites and Blacks.</p><table-wrap id="cam41153-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics and urinary estrogen metabolite (EM) levels of participants at baseline (<italic>n</italic>&#x000a0;=&#x000a0;51 subjects)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th><th align="left" valign="top" rowspan="1" colspan="1">Median <xref rid="cam41153-bib-0019" ref-type="ref">19</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (y)</td><td align="left" rowspan="1" colspan="1">58.1 (49.2&#x02013;78.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="left" rowspan="1" colspan="1">163.1 (152.1&#x02013;179.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="left" rowspan="1" colspan="1">73.2 (42.1&#x02013;117.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">26.9 (17.8&#x02013;42.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Years since last menses</td><td align="left" rowspan="1" colspan="1">12.0 (0.0&#x02013;38.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Parity, no. of live births</td><td align="left" rowspan="1" colspan="1">2.0 (0.0&#x02013;8.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Number (%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Educational level</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;High school</td><td align="left" rowspan="1" colspan="1">5 (10.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">High school graduate</td><td align="left" rowspan="1" colspan="1">17 (34.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">College/graduate work</td><td align="left" rowspan="1" colspan="1">28 (56.0)</td></tr><tr><td align="left" colspan="2" rowspan="1">Parous</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">43 (84.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">8 (15.7)</td></tr><tr><td align="left" colspan="2" rowspan="1">Menopause type</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Natural</td><td align="left" rowspan="1" colspan="1">42 (82.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hysterectomy</td><td align="left" rowspan="1" colspan="1">9 (17.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Urinary EM (pmol/mg creatinine)</td><td align="left" rowspan="1" colspan="1">Median <xref rid="cam41153-bib-0019" ref-type="ref">19</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total parent estrogens and metabolites</td><td align="left" rowspan="1" colspan="1">36.30 (7.26&#x02013;198.63)</td></tr><tr><td align="left" rowspan="1" colspan="1">Parent estrogens</td><td align="left" rowspan="1" colspan="1">7.46 (0.61&#x02013;68.57)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Estrone (E1)</td><td align="left" rowspan="1" colspan="1">6.01 (0.31&#x02013;56.21)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Estradiol (E2)</td><td align="left" rowspan="1" colspan="1">1.50 (0.31&#x02013;12.36)</td></tr><tr><td align="left" colspan="2" rowspan="1">2&#x02010;Hydroxylation pathway</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2&#x02010;Hydroxylation pathway catechols</td><td align="left" rowspan="1" colspan="1">9.24 (1.70&#x02013;63.41)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2&#x02010;Hydroxyestrone (2&#x02010;OHE1)</td><td align="left" rowspan="1" colspan="1">7.41 (1.48&#x02013;53.16)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2&#x02010;Hydroxyestradiol (2&#x02010;OHE2)</td><td align="left" rowspan="1" colspan="1">5.89 (0.51&#x02013;45.70)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2&#x02010;Hyroxylation pathway methylated catechols</td><td align="left" rowspan="1" colspan="1">1.25 (0.12&#x02013;7.47)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2&#x02010;Methoxyestrone (2&#x02010;MeOE1)</td><td align="left" rowspan="1" colspan="1">1.74 (0.21&#x02013;10.24)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2&#x02010;Methoxyestradiol (2&#x02010;MeOE2)</td><td align="left" rowspan="1" colspan="1">1.23 (0.05&#x02013;8.47)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2&#x02010;Hydroxyestrone&#x02010;3&#x02010;methyl ether (3&#x02010;MeOE1)</td><td align="left" rowspan="1" colspan="1">0.19 (0.03&#x02013;0.97)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.27 (0.01&#x02013;0.96)</td></tr><tr><td align="left" colspan="2" rowspan="1">4&#x02010;Hydroxylation pathway</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">4&#x02010;Hydroxylation pathway catechols</td><td align="left" rowspan="1" colspan="1">1.06 (0.11&#x02013;17.77)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">4&#x02010;Hydroxyestrone (4&#x02010;OHE1)</td><td align="left" rowspan="1" colspan="1">
<xref ref-type="fn" rid="cam41153-note-0002">a</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">4&#x02010;Hydroxylation pathway methylated catechols</td><td align="left" rowspan="1" colspan="1">0.90 (0.01&#x02013;16.99)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">4&#x02010;Methoxyestrone (4&#x02010;MeOE1)</td><td align="left" rowspan="1" colspan="1">0.19 (0.03&#x02013;1.86)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">4&#x02010;Methoxyestradiol (4&#x02010;MeOE2)</td><td align="left" rowspan="1" colspan="1">0.14 (0.002&#x02013;1.85)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.03 (0.002&#x02013;0.22)</td></tr><tr><td align="left" colspan="2" rowspan="1">16&#x003b1;&#x02010;Hydroxylation pathway</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">16&#x003b1;&#x02010;Hydroxyestrone (16&#x003b1;&#x02010;OHE1)</td><td align="left" rowspan="1" colspan="1">16.87 (4.34&#x02013;73.35)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Estriol (E3)</td><td align="left" rowspan="1" colspan="1">3.38 (0.80&#x02013;15.30)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">17&#x02010;Epiestriol (17&#x02010;epiE3)</td><td align="left" rowspan="1" colspan="1">6.91 (0.49&#x02013;38.10)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">16&#x02010;Ketoestradiol (16&#x02010;ketoE2)</td><td align="left" rowspan="1" colspan="1">0.37 (0.02&#x02013;2.01)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">16&#x02010;Epiestriol (16&#x02010;epiE3)</td><td align="left" rowspan="1" colspan="1">4.62 (1.02&#x02013;34.41)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.21 (0.13&#x02013;7.02)</td></tr></tbody></table><table-wrap-foot><fn id="cam41153-note-0002"><label>a</label><p>4&#x02010;Hydroxyestrone is the only 4&#x02010;Hydroxylation pathway catechol we measured; therefore, the medians and ranges are the same for both these measures.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Table&#x000a0;<xref rid="cam41153-tbl-0002" ref-type="table-wrap">2</xref> shows participants&#x02019; mean urinary EM concentrations and mean differences after consumption of no alcohol (placebo), 15&#x000a0;g/d, and 30&#x000a0;g/d alcohol. Low (15&#x000a0;g/d) alcohol consumption for 8&#x000a0;weeks versus the placebo had no effect on total parent estrogen metabolites or any of the 15 urinary EM concentrations. However, moderate (30&#x000a0;g/d) alcohol consumption (compared to none) decreased 2&#x02010;OHE1 by 3.3% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.055) and increased 16&#x02010;epiE3 by 26.6%. (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.037). Trends for reduced urinary 2&#x02010;OHE1 (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.0454), a reduced ratio of the 2&#x02010;OH:16&#x02010;OH pathways and increased 16&#x02010;epiE3 (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.0347) were observed as alcohol dose increased from 0&#x000a0;g to 15&#x000a0;g to 30&#x000a0;g/d. There were no differences in the findings by race.</p><table-wrap id="cam41153-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Alcohol effects: mean urinary estrogen metabolites (EM) concentrations (pmol/mg creatinine), mean differences (delta), and 95% CI in urinary EM between no alcohol and when consuming 15&#x02010; and 30&#x000a0;g/day</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">No alcohol mean (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">0 vs. 15&#x000a0;g/day delta (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">0 vs. 30&#x000a0;g delta (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>&#x02010;trend</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Week 8</td></tr><tr><td align="left" rowspan="1" colspan="1">Total parent estrogens and metabolites</td><td align="left" rowspan="1" colspan="1">45.50 (36.96&#x02013;54.05)</td><td align="left" rowspan="1" colspan="1">0.74 (&#x02212;4.41&#x02013;5.90)</td><td align="left" rowspan="1" colspan="1">2.80 (&#x02212;3.83&#x02013;9.44)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Parent estrogens</td><td align="left" rowspan="1" colspan="1">10.45 (8.51&#x02013;12.40)</td><td align="left" rowspan="1" colspan="1">0.23 (&#x02212;0.50&#x02013;0.98)</td><td align="left" rowspan="1" colspan="1">0.69 (&#x02212;0.65&#x02013;2.03)</td><td align="left" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">Estrone (E1)</td><td align="left" rowspan="1" colspan="1">7.92 (6.42&#x02013;9.42)</td><td align="left" rowspan="1" colspan="1">0.17 (&#x02212;0.44&#x02013;0.79)</td><td align="left" rowspan="1" colspan="1">0.44 (&#x02212;0.57&#x02013;1.45)</td><td align="left" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Estradiol (E2)</td><td align="left" rowspan="1" colspan="1">2.54 (2.03&#x02013;3.04)</td><td align="left" rowspan="1" colspan="1">0.06 (&#x02212;0.18&#x02013;0.31)</td><td align="left" rowspan="1" colspan="1">0.25 (&#x02212;0.12&#x02013;0.62)</td><td align="left" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">2&#x02010;Hydroxylation pathway</td><td align="left" rowspan="1" colspan="1">13.67 (11.75&#x02013;15.59)</td><td align="left" rowspan="1" colspan="1">0.18 (&#x02212;1.52&#x02013;1.89)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.05 (&#x02212;2.57&#x02013;2.47)</td><td align="left" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">2&#x02010;Hydroxylation pathway catechols</td><td align="left" rowspan="1" colspan="1">11.27 (9.44&#x02013;13.11)</td><td align="left" rowspan="1" colspan="1">0.26 (&#x02212;1.37&#x02013;1.90)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.17 (&#x02212;2.28&#x02013;1.93)</td><td align="left" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">2&#x02010;Hydroxyestrone (2&#x02010;OHE1)</td><td align="left" rowspan="1" colspan="1">9.07 (7.19&#x02013;10.94)</td><td align="left" rowspan="1" colspan="1">0.19 (&#x02212;1.37&#x02013;1.74)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.30 (&#x02212;2.11&#x02013;1.50)<xref ref-type="fn" rid="cam41153-note-0004">a</xref>
</td><td align="left" rowspan="1" colspan="1">0.045</td></tr><tr><td align="left" rowspan="1" colspan="1">2&#x02010;Hydroxyestradiol (2&#x02010;OHE2)</td><td align="left" rowspan="1" colspan="1">2.21 (1.72&#x02013;2.70)</td><td align="left" rowspan="1" colspan="1">0.08 (&#x02212;0.23&#x02013;0.39)</td><td align="left" rowspan="1" colspan="1">0.13 (&#x02212;0.33&#x02013;0.59)</td><td align="left" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" rowspan="1" colspan="1">2&#x02010;Hydroxylation pathway methylated catechols</td><td align="left" rowspan="1" colspan="1">2.40 (1.96&#x02013;2.83)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.07 (&#x02212;0.35&#x02013;0.19)</td><td align="left" rowspan="1" colspan="1">0.11 (&#x02212;0.36&#x02013;0.60)</td><td align="left" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">2&#x02010;Methoxyestrone (2&#x02010;MeOE1)</td><td align="left" rowspan="1" colspan="1">1.72 (1.37&#x02013;2.06)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.01 (&#x02212;0.20&#x02013;0.17)</td><td align="left" rowspan="1" colspan="1">0.13 (&#x02212;0.23&#x02013;0.49)</td><td align="left" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">2&#x02010;Methoxyestradiol (2&#x02010;MeOE2)</td><td align="left" rowspan="1" colspan="1">0.28 (0.22&#x02013;0.34)</td><td align="left" rowspan="1" colspan="1">0.01 (&#x02212;0.04&#x02013;0.06)</td><td align="left" rowspan="1" colspan="1">0.02 (&#x02212;0.05&#x02013;0.08)</td><td align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">2&#x02010;Hydroxyestrone&#x02010;3&#x02010;methyl ether (3&#x02010;MeOE1)</td><td align="left" rowspan="1" colspan="1">0.40 (0.23&#x02013;0.57)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.07 (&#x02212;0.24&#x02013;0.10)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.02 (&#x02212;0.21&#x02013;0.16)</td><td align="left" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">4&#x02010;Hydroxylation pathway</td><td align="left" rowspan="1" colspan="1">4.93 (&#x02212;0.90&#x02013;10.78)</td><td align="left" rowspan="1" colspan="1">&#x02212;2.05 (&#x02212;8.01&#x02013;3.89)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.15 (&#x02212;2.80&#x02013;2.48)</td><td align="left" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">4&#x02010;Hydroxylation pathway EM catechols</td><td align="left" rowspan="1" colspan="1">
<xref ref-type="fn" rid="cam41153-note-0005">b</xref>
</td><td align="left" rowspan="1" colspan="1">
<xref ref-type="fn" rid="cam41153-note-0005">b</xref>
</td><td align="left" rowspan="1" colspan="1">
<xref ref-type="fn" rid="cam41153-note-0005">b</xref>
</td><td align="left" rowspan="1" colspan="1">
<xref ref-type="fn" rid="cam41153-note-0005">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">4&#x02010;Hydroxyestrone (4&#x02010;OHE1)</td><td align="left" rowspan="1" colspan="1">4.67 (&#x02212;1.12&#x02013;10.47)</td><td align="left" rowspan="1" colspan="1">&#x02212;2.03 (&#x02212;7.99&#x02013;3.92)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.16 (&#x02212;2.80&#x02013;2.47)</td><td align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">4&#x02010;Hydroxylation pathway methylated catechols</td><td align="left" rowspan="1" colspan="1">0.26 (0.20&#x02013;0.32)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.02 (&#x02212;0.06&#x02013;0.01)</td><td align="left" rowspan="1" colspan="1">0.004 (&#x02212;0.03&#x02013;0.04)</td><td align="left" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">4&#x02010;Methoxyestrone (4&#x02010;MeOE1)</td><td align="left" rowspan="1" colspan="1">0.20 (0.14&#x02013;0.26)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.02 (&#x02212;0.05&#x02013;0.02)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.001(&#x02212;0.03&#x02013;0.03)</td><td align="left" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" rowspan="1" colspan="1">4&#x02010;Methoxyestradiol (4&#x02010;MeOE2)</td><td align="left" rowspan="1" colspan="1">0.06 (0.05&#x02013;0.07)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.01 (&#x02212;0.02&#x02013;0.01)<xref ref-type="fn" rid="cam41153-note-0004">a</xref>
</td><td align="left" rowspan="1" colspan="1">0.01 (&#x02212;0.01&#x02013;0.02)</td><td align="left" rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" rowspan="1" colspan="1">16&#x003b1;&#x02010;Hydroxylation pathway</td><td align="left" rowspan="1" colspan="1">16.43 (14.50&#x02013;18.35)</td><td align="left" rowspan="1" colspan="1">2.37 (0.32&#x02013;4.42)</td><td align="left" rowspan="1" colspan="1">2.32 (&#x02212;0.14&#x02013;4.80)</td><td align="left" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">16&#x003b1;&#x02010;Hydroxyestrone (16&#x003b1;&#x02010;OHE1)</td><td align="left" rowspan="1" colspan="1">3.31 (2.86&#x02013;3.76)</td><td align="left" rowspan="1" colspan="1">0.07 (&#x02212;0.19&#x02013;0.34)</td><td align="left" rowspan="1" colspan="1">0.10 (&#x02212;0.29&#x02013;0.49)</td><td align="left" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">Estriol (E3)</td><td align="left" rowspan="1" colspan="1">7.39 (6.27&#x02013;8.51)</td><td align="left" rowspan="1" colspan="1">0.44 (&#x02212;1.64&#x02013;2.53)</td><td align="left" rowspan="1" colspan="1">1.39 (&#x02212;0.02&#x02013;2.80)</td><td align="left" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">17&#x02010;Epiestriol (17&#x02010;epiE3)</td><td align="left" rowspan="1" colspan="1">0.41 (0.28&#x02013;0.54)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.001 (&#x02212;0.07&#x02013;0.07)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.02 (&#x02212;0.13&#x02013;0.08)</td><td align="left" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1">16&#x02010;Ketoestradiol (16&#x02010;ketoE2)</td><td align="left" rowspan="1" colspan="1">4.07 (3.54&#x02013;4.61)</td><td align="left" rowspan="1" colspan="1">0.36 (0.003&#x02013;0.71)</td><td align="left" rowspan="1" colspan="1">0.53 (&#x02212;0.08&#x02013;1.14)</td><td align="left" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">16&#x02010;Epiestriol (16&#x02010;epiE3)</td><td align="left" rowspan="1" colspan="1">1.24 (1.07&#x02013;1.41)</td><td align="left" rowspan="1" colspan="1">0.01 (&#x02212;0.03&#x02013;0.23)</td><td align="left" rowspan="1" colspan="1">0.33 (&#x02212;0.14&#x02013;0.68)<xref ref-type="fn" rid="cam41153-note-0006">c</xref>
</td><td align="left" rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" rowspan="1" colspan="1">Ratio of 2&#x02010;OH:16&#x02010;OH pathways</td><td align="left" rowspan="1" colspan="1">0.91 (0.77&#x02013;1.05)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.07 (&#x02212;0.18&#x02013;0.03)</td><td align="left" rowspan="1" colspan="1">0.10 (&#x02212;0.20&#x02013;&#x02212;0.00007)</td><td align="left" rowspan="1" colspan="1">0.008</td></tr></tbody></table><table-wrap-foot><fn id="cam41153-note-0003"><p>Data shown in the table are crude (unadjusted) arithmetic means and differences. <italic>P</italic>&#x02010;trends are from mixed linear models adjusted for age, race, and BMI.</p></fn><fn id="cam41153-note-0004"><label>a</label><p>
<italic>P</italic>&#x000a0;=&#x000a0;0.055 (from <italic>t</italic>&#x02010;test based on log&#x02010;transformed data).</p></fn><fn id="cam41153-note-0005"><label>b</label><p>4&#x02010;Hydroxyestrone is the only 4&#x02010;Hydroxylation pathway catechol we measured; therefore, results are the same for both of these measures.</p></fn><fn id="cam41153-note-0006"><label>c</label><p>
<italic>P</italic>&#x000a0;=&#x000a0;0.037 (from <italic>t</italic>&#x02010;test based on log&#x02010;transformed data).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Compared to normal weight women (BMI&#x000a0;&#x02264;&#x000a0;25; <italic>n</italic>&#x000a0;=&#x000a0;15), overweight (BMI&#x000a0;&#x0003e;&#x000a0;25 to &#x02264;30; <italic>n</italic>&#x000a0;=&#x000a0;20) and obese (BMI&#x000a0;&#x0003e;&#x000a0;30; <italic>n</italic>&#x000a0;=&#x000a0;15) women both showed a consistent trend (<italic>P&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.05) for increased urinary excretion of E1 and E2. Overweight and obese women also trended to higher urinary excretion of E3 and 16&#x02010;epiE3 in the no alcohol group (data not shown).</p></sec><sec id="cam41153-sec-0007"><title>Discussion</title><p>This is the first study to use a randomized, controlled, crossover trial to determine the effects of low&#x02010;to&#x02010;moderate alcohol ingestion on urinary EMs. Metabolism of the parent estrogens, E1 and E2 leads to the production of estrogen metabolities which can be measured in the urine, and several of these urinary metabolites are hypothesized to influence breast cancer risk due to their estrogenic, mitogenic, and genotoxic activities.</p><p>In this study, we found that moderate alcohol consumption had a modest but discernable influence on estrogen metabolism, as evidenced by decreased urinary concentrations of 2&#x02010;OHE1 and increased 16&#x02010;epiE3. Low&#x02010;to&#x02010;moderate alcohol doses did not affect any of the other 13 urinary EMs measured in the study. Our results also indicate that the alcohol effect on EM appeared to differ by pathway, apparently stimulating the 16&#x003b1;&#x02010;hydroxylation pathway and leading to an increase in the end&#x02010;product 16&#x02010;epiE3, while suppressing the 2&#x02010;hydroxylation pathway resulting in a decrease in 2&#x02010;OHE1 (Table&#x000a0;<xref rid="cam41153-tbl-0002" ref-type="table-wrap">2</xref>). None of the other pathways or individual EMs were affected by low&#x02010;to&#x02010;moderate alcohol ingestion.</p><p>Since we measured EM in urine samples (excretion), our data are not directly comparable to estrogens in serum samples (circulation). We previously reported from the WAS that low&#x02010;to&#x02010;moderate alcohol consumption increased serum concentrations of estrone sulfate and DHEAS <xref rid="cam41153-bib-0009" ref-type="ref">9</xref>, <xref rid="cam41153-bib-0010" ref-type="ref">10</xref>. There is also evidence that serum EMs increase postmenopausal breast cancer risk <xref rid="cam41153-bib-0013" ref-type="ref">13</xref>. Recent evidence indicates that postmenopausal breast cancer risk increases with higher levels of 16&#x02010;epiE3 and decreases with lower levels of 2&#x02010;OHE1 in different prospective cohorts <xref rid="cam41153-bib-0004" ref-type="ref">4</xref>. Since moderate alcohol consumption in our study of postmenopausal women increased 16&#x02010;epiE3 and lowered 2&#x02010;OHE1, these results imply that moderate drinking may have dual effects on later breast cancer development, but this finding needs confirmation. We also assessed alcohol effects on the ratio of the 2&#x02010;OH:16&#x02010;OH pathways, a common metric in previous breast cancer epidemiology research <xref rid="cam41153-bib-0004" ref-type="ref">4</xref>, <xref rid="cam41153-bib-0014" ref-type="ref">14</xref>, and found that the ratio of these pathways decreased monotonically as alcohol dose increased from 0&#x000a0;g to 15&#x000a0;g to 30&#x000a0;g/d. To date, only one prospective study of urine concentrations of the ratio of the 2&#x02010;OH:16&#x02010;OH pathways in postmenopausal breast cancer risk has been published and no association was reported <xref rid="cam41153-bib-0014" ref-type="ref">14</xref>. Since even low&#x02010;dose alcohol consumption increases breast cancer risk <xref rid="cam41153-bib-0015" ref-type="ref">15</xref>, the effects of low&#x02010;to&#x02010;moderate drinking on breast cancer risk probably have biological effects other than on EM. There is also strong evidence that low&#x02010;to&#x02010;moderate levels of alcohol consumption protect against heart disease <xref rid="cam41153-bib-0016" ref-type="ref">16</xref>, so it is important to determine both the harms and benefits of light drinking.</p><p>We also assessed the effects of BMI on urinary estrogen metabolites measured in the study and found a consistent trend for increased concentrations of E1 and E2 with overweight and obesity within all alcohol doses. The main source of estrogen in postmenopausal women is from the conversion of androgens in the adipose tissue, and this presumably leads to higher exposure of breast cells to estrogens. Therefore, postmenopausal women with higher BMI are expected to have higher concentrations of estrogens. We and others <xref rid="cam41153-bib-0017" ref-type="ref">17</xref>, <xref rid="cam41153-bib-0018" ref-type="ref">18</xref> have previously reported that postmenopausal women with higher levels of adiposity have higher levels of serum estrogen concentrations.</p><p>There are obvious strengths and limitations to the current research. Unlike observational studies in which alcohol dose and type are estimated based on questionnaires, we provided precise doses for a known duration under controlled diet conditions of weight maintenance. Controlled dietary conditions are important because diet has been shown to influence hormone concentrations, diet is highly variable in Western society, and our methods for measuring dietary intake in free&#x02010;living (and free eating) persons (typically by self&#x02010;reports via questionnaires) are poor. In addition, the crossover design of the study allowed participants to serve as their own controls and to increase power. However, this is a small study and the results may be affected by multiple comparisons.</p><p>In conclusion, our results suggest that moderate alcohol consumption, equivalent to two drinks per day, for 8&#x000a0;weeks influenced EM. We observed increased urinary 16&#x02010;epiE3 and decreased 2&#x02010;OHE1, suggesting that alcohol may affect EM pathways differently, stimulating some and suppressing others.</p></sec><sec id="cam41153-sec-0008"><title>Conflict of Interest</title><p>None declared.</p></sec></body><back><ref-list content-type="cited-references" id="cam41153-bibl-0001"><title>References</title><ref id="cam41153-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cam41153-cit-0001">
<string-name>
<surname>Wellsjus</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Olsen</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Tjonneland</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Thomsen</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Overvad</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Loft</surname>
</string-name>. <year>2005</year>
<article-title>Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study</article-title>. <source>Cancer Epidemiol. Biomarkers Prev.</source>
<volume>14</volume>:<fpage>2137</fpage>&#x02013;<lpage>2142</lpage>.<pub-id pub-id-type="pmid">16172222</pub-id></mixed-citation></ref><ref id="cam41153-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cam41153-cit-0002">
<string-name>
<surname>Ziegler</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Faupel&#x02010;Badger</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Sue</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Fuhrman</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Falk</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Boyd&#x02010;Morin</surname>
</string-name>, et&#x000a0;al. <year>2010</year>
<article-title>A new approach to measuring estrogen exposure and metabolism in epidemiologic studies</article-title>. <source>J. Steroid Biochem. Mol. Biol.</source>
<volume>121</volume>:<fpage>538</fpage>&#x02013;<lpage>545</lpage>.<pub-id pub-id-type="pmid">20382222</pub-id></mixed-citation></ref><ref id="cam41153-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cam41153-cit-0003">
<string-name>
<surname>Eliassen</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Spiegelman</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Keefer</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Veenstra</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Barbieri</surname>
</string-name>, et&#x000a0;al. <year>2011</year>
<article-title>Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women</article-title>. <source>Cancer Res.</source>
<volume>72</volume>:<fpage>696</fpage>&#x02013;<lpage>706</lpage>.<pub-id pub-id-type="pmid">22144471</pub-id></mixed-citation></ref><ref id="cam41153-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cam41153-cit-0004">
<string-name>
<surname>Sampson</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Falk</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Schairer</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Moore</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Fuhrman</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Dallal</surname>
</string-name>, et&#x000a0;al. <year>2017</year>
<article-title>Association of estrogen metabolism with breast cancer risk in different cohorts of postmenopausal women</article-title>. <source>Cancer Res.</source>
<volume>77</volume>:<fpage>1</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="cam41153-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cam41153-cit-0005">
<string-name>
<surname>Yager</surname>, <given-names>J.</given-names>
</string-name>
<year>2000</year>
<article-title>Endogenous estrogens as carcinogens through metabolic activation</article-title>. <source>J. Natl. Cancer Inst. Monogr.</source>
<volume>27</volume>:<fpage>67</fpage>&#x02013;<lpage>73</lpage>.</mixed-citation></ref><ref id="cam41153-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cam41153-cit-0006">
<string-name>
<surname>Driggers</surname>, <given-names>P.</given-names>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Segars</surname>
</string-name>. <year>2002</year>
<article-title>Estrogen action and cytoplasmic signalling pathways. Part II: the role of growth factors and phosphorylation in estrogen signalling</article-title>. <source>Trends Endrocrinol. Metabol.</source>
<volume>13</volume>:<fpage>422</fpage>&#x02013;<lpage>427</lpage>.</mixed-citation></ref><ref id="cam41153-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cam41153-cit-0007">
<string-name>
<surname>Cid</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Schanaper</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Kleinmann</surname>
</string-name>. <year>2002</year>
<article-title>Estrogens and the vascular endothelium</article-title>. <source>Ann. N.Y. Acad. Sci.</source>
<volume>966</volume>:<fpage>143</fpage>&#x02013;<lpage>157</lpage>.<pub-id pub-id-type="pmid">12114268</pub-id></mixed-citation></ref><ref id="cam41153-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cam41153-cit-0008">
<string-name>
<surname>Elkin</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Orgel</surname>
</string-name>, and <string-name>
<given-names>K.</given-names>
<surname>Kleinman</surname>
</string-name>. <year>2004</year>
<article-title>An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor 1</article-title>. <source>J. Natl Cancer Inst.</source>
<volume>96</volume>:<fpage>875</fpage>&#x02013;<lpage>881</lpage>.<pub-id pub-id-type="pmid">15173272</pub-id></mixed-citation></ref><ref id="cam41153-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cam41153-cit-0009">
<string-name>
<surname>Dorgan</surname>, <given-names>J. F.</given-names>
</string-name>, <string-name>
<given-names>D. J.</given-names>
<surname>Baer</surname>
</string-name>, <string-name>
<given-names>P. S.</given-names>
<surname>Albert</surname>
</string-name>, <string-name>
<given-names>J. T.</given-names>
<surname>Judd</surname>
</string-name>, <string-name>
<given-names>E. D.</given-names>
<surname>Brown</surname>
</string-name>, <string-name>
<given-names>D. K.</given-names>
<surname>Corle</surname>
</string-name>, et&#x000a0;al. <year>2001</year>
<article-title>Serum hormones and the alcohol&#x02010;breast cancer association in postmenopausal women</article-title>. <source>J. Natl Cancer Inst.</source>
<volume>93</volume>:<fpage>710</fpage>&#x02013;<lpage>715</lpage>.<pub-id pub-id-type="pmid">11333294</pub-id></mixed-citation></ref><ref id="cam41153-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cam41153-cit-0010">
<string-name>
<surname>Mahabir</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Baer</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Johnson</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Dorgan</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Campbell</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Brown</surname>
</string-name>, et&#x000a0;al. <year>2004</year>
<article-title>The effects of moderate alcohol supplementation on estrone sulfate and DHEAS in postmenopausal women in a controlled feeding study</article-title>. <source>Nutr. J.</source>
<volume>3</volume>:<fpage>11</fpage>.<pub-id pub-id-type="pmid">15353002</pub-id></mixed-citation></ref><ref id="cam41153-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cam41153-cit-0011">
<string-name>
<surname>Calle</surname>, <given-names>E.</given-names>
</string-name>, and <string-name>
<given-names>R.</given-names>
<surname>Kaaks</surname>
</string-name>. <year>2004</year>
<article-title>Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms</article-title>. <source>Nat. Rev.</source>
<volume>4</volume>:<fpage>579</fpage>&#x02013;<lpage>591</lpage>.</mixed-citation></ref><ref id="cam41153-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cam41153-cit-0012">
<string-name>
<surname>Falk</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Keefer</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Veenstra</surname>
</string-name>, and <string-name>
<given-names>R.</given-names>
<surname>Ziegler</surname>
</string-name>. <year>2008</year>
<article-title>A liquid chromatography&#x02010;mass spectrometry method for the simultaneous measurement of 15 urinary estrogens and estrogen metabolites: assay reproducibility and interindividual variability</article-title>. <source>Cancer Epidemiol. Biomarkers Prev.</source>
<volume>17</volume>:<fpage>3411</fpage>&#x02013;<lpage>3418</lpage>.<pub-id pub-id-type="pmid">19064556</pub-id></mixed-citation></ref><ref id="cam41153-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cam41153-cit-0013">
<string-name>
<surname>Fuhrman</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Schairer</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Gail</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Boyd&#x02010;Morin</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Su</surname>
</string-name>, et&#x000a0;al. <year>2012</year>
<article-title>Estrogen metabolism and risk of breast cancer in postmenopausal women</article-title>. <source>J. Natl Cancer Inst.</source>
<volume>104</volume>:<fpage>1</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="cam41153-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cam41153-cit-0014">
<string-name>
<surname>Moore</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Matthews</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Ou Shu</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Yu</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Gail</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Xu</surname>
</string-name>, et&#x000a0;al. <year>2016</year>
<article-title>Endogenous estrogens, estrogen metabolites, and breast cancer risk in postmenopausal Chinese women</article-title>. <source>J. Natl Cancer Inst.</source>
<volume>108</volume>(<issue>10</issue>):<fpage>djw103</fpage>.</mixed-citation></ref><ref id="cam41153-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cam41153-cit-0015">
<string-name>
<surname>Shield</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Soerjomataram</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Rehm</surname>
</string-name>. <year>2016</year>
<article-title>Alcohol use and breast cancer: a critical review</article-title>. <source>Alcohol. Clin. Exp. Res.</source>
<volume>40</volume>:<fpage>1166</fpage>&#x02013;<lpage>1181</lpage>.<pub-id pub-id-type="pmid">27130687</pub-id></mixed-citation></ref><ref id="cam41153-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cam41153-cit-0016">
<string-name>
<surname>Klatsky</surname>, <given-names>A.</given-names>
</string-name>
<year>2015</year>
<article-title>Alcohol and cardiovascular diseases: where do we stand today?</article-title>
<source>J. Intern. Med.</source>
<volume>278</volume>:<fpage>238</fpage>&#x02013;<lpage>250</lpage>.<pub-id pub-id-type="pmid">26158548</pub-id></mixed-citation></ref><ref id="cam41153-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cam41153-cit-0017">
<string-name>
<surname>Mahabir</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Baer</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Johnson</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Hartman</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Dorgan</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Campbell</surname>
</string-name>, et&#x000a0;al. <year>2006</year>
<article-title>Usefulness of body mass index as a sufficient adiposity measurement for sex hormone concentration associations in postmenopausal women</article-title>. <source>Cancer Epidemiol. Biomarkers Prev.</source>
<volume>15</volume>:<fpage>2502</fpage>&#x02013;<lpage>2507</lpage>.<pub-id pub-id-type="pmid">17164376</pub-id></mixed-citation></ref><ref id="cam41153-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cam41153-cit-0018">
<string-name>
<surname>Yang</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Black</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Falk</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Brinton</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Potischman</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Wentzensen</surname>
</string-name>, et&#x000a0;al. <year>2011</year>
<article-title>Association of serum sex steroid hormone hemodilution and body mass index among healthy postmenopausal women</article-title>. <source>Ann. Epidemiol.</source>
<volume>21</volume>:<fpage>466</fpage>&#x02013;<lpage>471</lpage>.<pub-id pub-id-type="pmid">21435901</pub-id></mixed-citation></ref><ref id="cam41153-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cam41153-cit-0019">
<string-name>
<surname>Benhamou</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Alexandrie</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Boffetta</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Bouchardy</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Butkiewicz</surname>
</string-name>, et&#x000a0;al. <year>2002</year>
<article-title>Meta&#x02010; and pooled analyses of the effects of glutathione S&#x02010;transferase M1 polymorphisms and smoking on lung cancer risk</article-title>. <source>Carcinogenesis</source>
<volume>23</volume>:<fpage>1343</fpage>&#x02013;<lpage>1350</lpage>.<pub-id pub-id-type="pmid">12151353</pub-id></mixed-citation></ref></ref-list></back></article>